To address this challenge, researchers have developed the first nanobody-based inhibitors targeting the Ebola virus. Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50% ...
To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...
From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase conference in San Francisco and the Global Biopharma ...
New trials in three new indications have been initiated with the Nanobody® sonelokimab ... and pathologic bone formation and joint fusion, severely limiting spinal mobility.
This binding prevents the virus from utilizing its glycoprotein for attachment and fusion, thereby halting ... These findings support the potential of nanobody technology in addressing viral ...
To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...
MoonLake Immunotherapeutics AG New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback